PharmaBoardroom

The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the…

There is perhaps no Turkish company in the healthcare sector that is more ambitious than Acıbadem. Not only has the private hospital group…

Dr Joseph Tam is indisputably one of the pioneers of Hong Kong’s biotech industry, having returned to Hong Kong in 1973 following an illustrious…

In a market where revolutionary treatments and new technologies threaten to introduce structural changes, the need for national authorities and…

2009 marks 40 years of China’s liberalization and opening up under then-Premier Deng Xiaoping. Servier China also bears the distinction of having…

ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its…

Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical…

As one of the longest-standing multinational companies in Egypt, French pharmaceutical giant Sanofi aims to plays a major role in ensuring access to…

Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease…

The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones…

Orifarm is the largest supplier of parallel imported medicines in the EU and a fast-growing supplier of generic pharmaceuticals in the Nordic…

Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic…